DOI:
10.1055/s-00033990
TH Open
LinksClose Window
References
Flynn PJ, Sugrue MM, Purdie DM. , et al.
Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRiTE Observational Cohort Study.
J Clin Oncol 2008;
26 (Suppl 15): 4104
We do not assume any responsibility for the contents of the web pages of other providers.